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Abstract 
 
Cholera, caused by Vibrio cholerae O1/O139, is an acute dehydrating enteric disease 
with high mortality rate if untreated. Several efforts have been made to develop 
effective vaccines, and effort is still continuing. The available oral cholera vaccines 
provide protection for 3-5 years in adult and for shorter duration in younger children. 
However, it was observed that natural infections in cholera endemic areas provide 
longer term protective immunity lasting for 7-10 years, but the mechanism is not 
completely understood.  It was hypothesized that this protective immunity may be 
mediated by memory B cell responses. In this study 60 hospitalized cholera culture 
confirmed patients were evaluated for their immune response up to 180 days after 
onset of illness. A method of polyclonal stimulation of peripheral blood mononuclear 
cells followed by an enzyme-linked immunospot assay was used to study memory B 
cell responses specific to V. cholerae O1 antigens, lipopolysaccharide (LPS) and O-
specific polyscaccharide (OSP) of LPS. To observe circulating plasma antibody 
responses enzyme-linked immuno assay accompanied with memory B cell studies 
were carried out at different study points. All patients exhibited LPS and OSP-specific 
memory B cell proliferation by day 30. LPS-specific IgG and IgM memory B cell 
responses were elevated throughout the follow up days, while LPS IgA response 
magnitude waned down by day 90, but persisted up to day 180. However, OSP-
specific IgA, IgG and IgM memory B cell response were found at day 30. The OSP-
specific IgA and IgG memory B cell responses were elevated throughout the whole 
study period, while IgM responses started to wane down by day 180. Significant level 
of LPS and OSP-specific circulating plasma antibody for all the antibody isotypes 
were observed. Results suggested that such memory B cells might persist for longer 
period providing protective immunity against subsequent exposure to cholera. A 
vaccine, targeted to generate memory B cell, preferably OSP-specific will be 
important for evaluating effectiveness of vaccines and for design and formulation of 
future effective cholera vaccines.  
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1 Introduction 
1.1. Background 
Cholera, an ancient and devastating diarrheal illness continues to be a primary cause 
of morbidity and mortality in developing countries like Bangladesh (1, 2). It is the 
second leading cause of death among children‟s under five years of age globally. 
Approximate incidence of cholera is 3-5 million per year in Bangladesh. Cholera is an 
infection of intestine caused by ingestion of food or water containing Vibrio cholerae, 
gram negative bacteria resulting in acute secretory diarrhea (3, 4). Symptoms include 
loose or watery stools more frequently than normal for a healthy individual and 
vomiting which can result in severe dehydration or water loss. When left untreated, 
death can occur rapidly sometimes within hours. Cholera is transmitted through 
contaminated food or water and person to person contact through fecal-oral route (5). 
Although person to person direct transmission lacks proof, Vibrio cholerae from 
patient stool is hyper infectious (9).  
The serogroup of the causative agent is differentiated by the O-speciﬁc 
polysaccharide (OSP) portion of V. cholerae lipopolysaccharide (LPS) in the outer 
membrane of the bacterium. Among characterized more than 200 serogroups, only 
serogroups O1 and O139 are known to cause epidemic cholera (6). Natural infection 
by V. cholerae provides serogroup specific long term protection against subsequent 
disease, however the gold standard marker for this protection remain unknown (7). 
Long term protection refers to antibody production due to memory B cell response to 
subsequent exposure to the antigen OSP or LPS (8). Memory B cells response 
towards OSP still needs investigation vastly which may play crucial role in vaccine 
development. 
 
1.2. Cholera and clinical features 
Being diarrhea a bacterial disease, Vibrio cholerae is associated with most severe case 
of cholera with up to 30 liter of fluid loss per day with death rate of 30% (10). The 
sudden onset of profuse, watery stools with occasional vomiting is characterized as 
cholera (11). Incubation period is usually 2–5 days but may be only a few hours. In 
severe cases about 5–10% of infected, dehydration, metabolic acidosis, and 
circulatory collapse may rapidly develop. If left untreated, over 50% of the most 
  
 
2 Introduction 
severe cases patients may die within several hours. Proper treatment may reduce 
mortality to less than 1% (12). In its 18 h to 5 d incubation period, it may also be 
associated with muscle cramps, and complications related to dehydration and 
metabolic acidosis.  In its extreme manifestation, within 3-4 h of the onset of 
symptoms, a healthy person may become hypotensive and may die within 6-8 h. More 
commonly fatal cases progress to shock within 6-12 h with death (1). 
 
1.3. Salient features of Vibrio cholerae 
The Vibrio cholerae is a gram-negative rod from the „Vibrionaceae‟ family, 
characterized by single polar flagellum, because of which they are highly motile. The 
organism grows best in saline condition, although it can grow in low salinity when it 
is warm and contains sufficient nutrients, as found in coastal water and estuaries, 
associated with zooplankton and shellﬁsh in water. It uses chitin as a carbon and 
nitrogen sources, which induces natural competence in V. cholerae, suggesting that 
lateral gene transfer occurs in water, especially during zooplankton blooms. In water, 
V. cholerae enters a viable yet a nonculturable form, also called conditionally viable 
environmental cells (1, 4).  
 
 
 
 
 
 
 
 
 
Figure 1.1: structure of Vibrio cholerae 
http://www.biologyguide.net/biol1/3b_exchange.htm 
  
 
3 Introduction 
V. cholerae is a facultative anaerobe, non-spore-forming curved rod, about 1.4–2.6 
mm long, capable of respiratory and fermentative metabolism; it is well deﬁned 
biochemically and in DNA homology. The bacterium is oxidase positive and nitrate 
reducer with sheathed flagellum. 1% sodium chloride (NaCl) can stimulate growth of 
it. 
However, the ability of V. cholerae to grow in nutrient broth without added NaCl 
made it distinct from other Vibrio spp (14). It grows in alkaline conditions up to a 
maximum of pH 10 but is inhibited when the pH drops to 6 or below. V. cholerae 
requires 5-15mM Na+ for optimum growth (15). 
 
1.3.1. Classification of Vibrio cholerae 
Vibrio cholerae has been serogrouped on the basis of „O‟ antigen of 
lipopolysaccharide and classified into more than 200 serogroups. Among these 
serogroups O1 and O139 were known to be the cause of cholera in epidemic form (1, 
4).  Serotype O1 again is subdivided into two major serotypes Inaba and Ogawa, and 
two biotypes El tor and Classical. The prevalence of biotype varies with time (4, 16).  
Presence of a 2-O-methyl group in the non-reducing terminal sugar of the Ogawa 
OSP, that is absent in Inaba OSP differentiate between the two major serotypes 
Ogawa and Inaba. Ogawa serotype expresses antigen A, B, with small amount of C 
while Inaba expresses A and C (17, 18). Till date among the 7 pandemics, 6 occurred 
by Classical biotype but the 7th and the last which caused by El Tor. There is also 
another unstable and rare serotype Hikojima the third (4). 
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Figure 1.2: Schematic presentation of Vibrio cholerae classification. 
 
1.3.2. Cholera Toxin 
Cholera toxin (CT) is the virulence factor responsible for the massive secretory 
diarrhea seen in dehydrating cholera (19). Robert Koch was first to suggest CT as 
cholera causative agent in 1884 (20). The discovery of the three-dimensional structure 
of CT enhanced our understanding of this remarkable toxin. The structure of CT is 
shown in Figure 3. CT consists of two types of subunits heterodimeric A & 
homopentameric B. The larger A subunit (240 amino acids; MW 28 kD) forms the 
center, while the five B subunits (103 amino acids; MW 11 kD each; aggregate MW 
~56 kD) are located peripherally. Identical B (green, blue, purple, white, red, pink) 
monomers are arranged in a ring-like conﬁguration with each a single binding site for 
Vibrio cholerae 
O1 
El Tor Classical 
Ogawa (AB) 
Inaba (AC) 
Hikojima (ABC) 
serotype 
Biotypes 
O139 
Serogroups 
Epidemic 
  
 
5 Introduction 
the plasma membrane receptor of the jejunal intestinal epithelial cells, the 
monosialoganglioside GM1. The A subunit (yellow) consists of two distinct 
polypeptide chains tide chains CT-A1 (MW∼22,000 and CT-A2 (MW∼5,400) linked 
by a single disulﬁde bridge.  
 
 
 
 
 
 
 
 
 
The CT-A2 M polypeptide links and occupies the central channel and goes through 
the doughnut-like structure of the CT-B pentamer, tethering CT-A and CT-B subunits 
(19, 22). The A subunit of CT has over 82 per cent sequence identity with the 
Escherichia coli heat-labile enterotoxin (LT), while the B subunits of the former 
shares over 83 per cent sequence identity with the latter (21). 
 
 
 
 
 
 
  
Figure 1.3: Three dimensional structure of Cholera Toxin (CT) (22) 
  
 
6 Introduction 
1.3.3. Lipopolysaccharide (LPS) and O-Specific Polysaccharide (OSP) 
Lipopolysaccharides (LPS) are endotoxins invariably associated with gram-negative 
bacteria irrespective of pathogenicity. In bacteriology the term endotoxin refers 
lipopolysaccharide complex on the outer 
membrane of gram-negative pathogens, 
for example: Escherichia coli, 
salmonella, shigella etc. LPS participate 
in the physiological functions (24). Like 
all Gram-negative bacteria, LPS of 
Vibrio cholerae polysaccharide attached 
to a lipid component, named lipid A. 
The polysaccharide component is made 
of a core and a polymer of 
oligosaccharide molecules (O-antigen), 
which is immensely variable and 
specific to each bacterial strain. A sugar 
2-keto-3-deoxyoctulosonic acid (KDO) 
bounds the polysaccharide to lipid A. 
Lipid A is a peculiar bacterial lipid 
consisting of a phosphorylated β-1, 6-
linked glucosamine disaccharide, to 
which long fatty acids are attached. 
Expression of cytokines by LPS is 
assumed to be induced by Lipid A (25). 
LPS toxicity is associated with the lipid 
component (Lipid A) while immunogenicity is associated with the OSP components. 
LPS elicits a variety of inflammatory responses in an animal and it activates 
complement by the alternative (properdin) pathway, so it may be a part of the 
pathology of gram-negative bacterial infections (23). 
Toxicity is associated with lipid A component and that is why holo LPS antigen are 
not normally used as components of parenteral and injectable vaccines while the 
antigenic OSP on LPS is a virulence factor at the same time an important protective 
Figure 1.4: Schematic 
Lipopolysaccharides 
http://www.beilstein-
institut.de/glycobioinf2O11/Proceedings/Ste
nutz/Stenutz.html 
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agent of Vibrio cholerae and many other bacteria. LPS can be detoxified in many 
ways such as: mild hydrolysis with dilute acetic acid, separating the OSP core antigen 
from the Lipid A component (26). Small changes in LPS side chain sugar molecule 
result in major change in virulence while the O antigenic polysaccharide probably 
allows the organism to adhere to specific tissues in the mucoal surface. Smooth 
variants of bacteria probably allow resistance to phagocytosis, whereas rough mutants 
are more readily engulfed and destroyed by phagocytes. The „O‟ antigens could 
provide protection from damaging reactions with antibody and complement that 
makes it an important target for vaccine development. 
O antigen is the basis of antigenic variation among many important Gram-negative 
pathogens-including Vibrio cholerae, which guarantees the existence of multiple 
serotypes of the bacterium, so it offers multiple opportunities to infect its host if it can 
bypass the immune response against a different serotype (23). 
 
1.3.4. Pathogenesis of Vibrio cholerae 
Pathogenesis of Vibrio cholerae is a complex process (27). Most ingested bacteria are 
killed by gastric acid. The infectious dose of Vibrio cholerae with water is 10
3
 -10
6
 
and with food is 10
2
-10
4
. Organisms those can survive colonize the small intestine and 
secret Cholera Toxin (CT) the major virulence factor for cholera. There are a number 
of virulence genes encoding factor which aids the pathogens to reach the epithelium 
of small intestine, colonizes and produces enterotoxin. In addition to CT, 
pathogenicity of Vibrio cholerae depends primarily on the expression of a pilus 
colonization factor known as toxin co-regulated pilus (TCP), under same genetic 
control as CT (28). The action mechanism of cholera toxin (Figure: 5) that leads to 
acute diarrhea or cholera schematically described below: 
 
1. CT binds with high affinity GM1 receptor and actively gets internalized by host 
cell machinery into the early and recycling endosomes. 
  
 
8 Introduction 
2. It is transported as holotoxin in a retrograde manner to the Golgi and further to 
ER, where CT dissociates into CT-A1 and CT-A1/CT-B driven by PDI, that is also 
responsible for unfolding of CT-A1.  
3. The CT-A1 is further translocated via sec61 complex to the cytosol, where it 
associates with basolateral (Adenylate Cyclase) AC avoiding proteasomal 
degradation. 
4.  Mono-ADP-ribose get transported from NAD+ to GSα constitutively triggers the 
AC, resulting in substantial increase in intracellular concentration of cAMP, 
followed by a protein kinase (PKA)-mediated phosphorylation of the major 
Figure 1.5: Cholera toxin mode of action (22) 
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chloride channel of intestinal epithelial cells. This leads to increased Cl
-
 secretion, 
which is accompanied by osmotic movement of a large quantity of water into the 
intestinal lumen, resulting in severe diarrhea (22). 
 
1.4. Transmission 
Generally cholera infection is caused and transmitted by contaminated food and 
water. In developing countries the lack of proper sanitary facility is counted as a 
major reason of infection. In human stool Vibrio cholerae might be present as 
individual planktonic form or as biofilm aggregate (9, 29). This converts Vibrio 
cholerae to conditionally viable state in environment (30).  
 
 
1.5. Susceptibility and Risk Factors 
Previous studies suggested individual‟s susceptibility to cholera including other 
diarrheal diseases is influenced by their blood types. People with AB blood type are 
most resistant while with O blood is most susceptible. Among these two extremes 
blood types, type A are more resistant than type B (32, 33).  Typically 10
3
 -10
6 
is 
infectious dosage for cholera onset for healthy adult but people with lack of immunity 
and nutrition, gastric acidity is more susceptible (4, 34). Absence of several host 
factors is also responsible for increased risk of cholera (33, 35).  Cholera outbreak 
also depends on three major factors, those are: contamination of source of water, 
rainfall and natural disaster (36, 37). 
Figure 1.6: Transmission of Cholera (31) 
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1.6. Epidemiology of cholera 
1.6.1. Global Epidemiology 
Cholera is known as both endemic and pandemic disease (4). There are records 
suggesting that it affected people‟s health for decades. Human kind already faced 7 
major pandemics in last two centuries (1, 4). Cholera is endemic in many areas of 
Asia and Africa. Devastating cholera occured in Angola, Ethiopia, Zimbabwe, 
Pakistan, Somalia, Sudan, Vietnam, and Haiti. Cholera can be highly fatal in epidemic 
form irrespective of age groups, i.e. neonates to old are in equal risk (40). Among the 
seven devastating epidemics first five were reported to be originated from Bangladesh 
by classical O1 Vibrio cholerae biotype, but the last and seventh one reported was 
caused by O1 El Tor (1). Cholera outbreak causes estimated at 120,000 deaths 
annually worldwide and many more each year, among these the vast majority of 
affected are children.  The cholera case reports increased by 16 percent over the 
previous year in 2009, as reported by WHO (41).  WHO reported an estimation of 
cholera cases of about 500000 to 700000 in year 2O11. But this estimation was 
considered as significantly underestimated (43). Cholera epidemics occur in long 
cycle being superimposed on existing endemic disease that leads to declining level of 
immunity from a previous outbreak (4). 
 
 
 
 
 
  
 
11 Introduction 
 
Figure 1.7: Global outbreak of cholera since 2000 (37) 
 
1.6.2. Epidemiology of cholera in Bangladesh 
As Bangladesh is a developing country, cholera is an important public health concern 
due to lack of basic infrastructure with regard of safe water access and proper 
sanitation. Cholera continues to be a threat and a challenge to the growing population 
living in unsanitary condition such as shanty towns and refugee or displaced 
population camp (3). In Bangladesh cholera attacks show seasonality. There are two 
peaks every year, before the warm season and after the monsoon rains (42). Cholera 
infection strain in Bangladesh varied time to time. Until 1970, more than 90% cholera 
was caused by classical ogawa type, but in 1992 Vibrio cholerae O139 emerged and 
caused epidemic in the following year 1993 in southern area of Bangladesh including 
India and neighboring countries and spread to the other parts of the country (44). In 
1992, Approximately 220,000 cases were reported in a 12-week period, with over 
8,000 deaths (45). 
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1.7. Prevention and Control 
Prevention of cholera is simply a practice of healthy living with hygiene. And control 
of cholera refers to rapid action against any cholera outbreak at any place with proper 
medical facilities and supplies for reducing death rates. Vaccination might be most 
effective prevention and control over this cholera nightmare, although more 
investigation in this field yet to be done. 
Household practices that help to prevent Cholera to a great extents, are as follows: 
 Firstly, drinking pure water or boiled tube well water or after treating water with 
sterilizing tablets or chlorine or iodine. 
 Secondly, one should eat freshly prepared or cooked foods, taking green 
vegetables is good to health. Any kind of food must be cleaned thoroughly before 
eating. 
 Finally and most important, one should develop a regular practice of good hygiene 
(46). 
 
1.7.1. Oral Rehydration Solution Therapy 
Cholera is a disease in which rapid fluid and salt loss occur weakening the patient and 
thus can lead to death. Rapid restoration of fluid with salts is a common treatment for 
any patient and also effective in cases of cholera outbreak.  Medically patients are 
treated with oral rehydration solution (ORS) a package mixture of salts and sugars, 
which is drunk in a large amount mixing with water. This treatment is accepted 
Figure 1.8: Oral rehydration Salts 
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worldwide in cases of diarrhea and cholera but in cases where patients are severely 
dehydrated they must be treated with intra venous fluids (IVF) (47). 
 
1.7.2. Antibiotic therapy 
Although antibiotic therapy is not a part of emergency treatment but it is a good 
addition to reduce duration of diarrhea and period of Vibrio cholerae excretion with 
proper rehydration treatments. But Vibrio cholerae is getting resistant to available 
antibiotics like: tetracycline, erythromycin, cotrimoxazole. More effective antibiotics 
include: azathromycin, doxycycline, chloramphenicol and furazolidone (48). 
 
1.7.3. Vaccination 
An effective vaccine with proper vaccination program would be very effective in 
prevention of infectious Cholera and reduction of morbidity and mortality rates. The 
available vaccines in present days are not effective for long term protection against 
cholera (47).  
There are two major types of vaccines available now. They are: 
1. Killed WC-based vaccines and 
2. Genetically attenuated live vaccines 
There are two licensed commercial oral cholera vaccines: 
a. WC-rBS (Dukoral): Killed whole cells of V. cholerae O1 (Inaba and Ogawa, 
classical and El Tor) plus recombinant cholera toxin B subunit.  
b. Modified WC-only vaccines (mORCVAX and Shanchol): Killed whole cells of 
V. cholerae O1 (Inaba and Ogawa, classical and El Tor) and O139 (bivalent). 
 
 
 
 
  
 
14 Introduction 
1.8. Immunity 
Having the state of sufficient biological defenses to avoid infection, disease, or other 
unwanted biological invasion is immunity. Both specific and non-specific components 
include immunological components. The non-specific components act either as 
barriers or as eliminators of pathogens irrespective of antigenic specificity while, 
other components of the immune system adapt themselves to fight each new disease 
encountered by generating pathogen-specific immunity known as adaptive immunity. 
Immunity to any kind can be divided into two categories, which are: Innate immunity 
and Adaptive immunity. 
 
1.8.1. Innate immunity 
Innate immunity is natural and first line of defense mechanism in human body that is 
achieved at birth. When encountered with new pathogen response occurs in three 
phases (Figure: 9). First phase is where some preformed soluble molecules 
(antimicrobial enzymes, peptides and a complement system of plasma proteins) 
present in blood, extracellular fluids and epithelial secretions kill or weaken effect of 
pathogen by cell lysis or lyse the bacterial cell membrane. And in the second phase 
innate immunity components sense the presence of pathogen recognizing molecules 
those are not shared by host cell but of typical of a microbe and eliminate the 
infection by effector cells (76).  
Cellular components include: 
 Neutrophils and macrophase: Identify microbes and ingest them for intracellular 
digestion. 
 Dendritic Cells: Produce cytokines important in recruitment of leukocytes, one of 
many bridges between innate and adaptive immune systems. 
 Natural Killer Cells: Effector cells of innate immunity. They recognize infected 
cells and then kill them. 
 Other Classes of Lymphocytes: Like other lymphocytes, their antigen receptors 
are somatically rearranged (like B and T cells). However, in contrast to classical 
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lymphocytes, they have limited diversity. Examples include γδ T cells and B-1 
cells. 
Humoral Components 
 Complement System: A group of proteins that defend the body against microbe. 
 Cytokines of Innate Immunity: Products of dendritic cells, macrophase and 
other cells that act as mediator for cellular component of innate immunity. 
Examples include TNF, Interleukin-1 and IFN-γ. 
 Plasma Proteins of Innate Immunity: Acute phase proteins, for example C-
reactive protein and surfactant. 
 
1.8.2. Adaptive immunity 
If pathogen passes previously described two lines of defenses, the third phase takes 
the action by generating antigen specific lymphocytes that target the pathogen 
specifically to form long lasting memory cells (Figure: 9) (76). 
Adaptive immune system components are normally silent; however, when activated, 
they “adapt” to the presence of infectious agents by activating, proliferating, and 
creating potent mechanisms for neutralizing or eliminating the microbes. Adaptive 
immune responses are classified in two groups: Humoral immunity, mediated by 
antibodies produced by B lymphocytes, and Cell-mediated immunity, mediated by T 
lymphocytes. 
Two major groups of cells are important for effective immune response, T-
lymphocytes and Antigen presenting cell. Immune response is generated when 
Figure 1.9: innate immunity and progression to adaptive immunity (76) 
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Antigen Presenting Cell (APC) represent the antigen to helper T-lymphocytes (Th) 
and signals B-cells to release antigen specific antibody as response. This process can 
generate both humoral and cell mediated immune response. 
 
1.8.2.1. Antigen presenting cells (APC) 
APCs trap the processed antigens (may be bacteria or bacterial part) from the 
invading organism on surface groove of Major Histocompatibility complex (MHC) 
class-II. This makes the antigen identifiable to the Th-cells (Figure: 10) (49). 
 
1.8.2.2. T-lymphocytes 
T-lymphocytes arise from bone marrow and migrate to thymus. There are two major 
subpopulations of T-lymphocytes: T-helper (Th) and T-cytotoxic (Tc) cells. Th-cells 
are termed as “middleman” of adaptive immunity. Th-cells signals B-cells when 
identifies the antigen in MHC Class-II groove by T Cell Receptor (TCR). T-cells also 
release cytokines (IL-2 and IL-4, 5, 6 or IFNγ) which stimulates B-cells to proliferate 
and differentiate into Antibody Secreting Cells (ASC) (49, 50).  
 
Figure 1.10: Activation of T cells by APC 
http://www.anselm.edu/homepage/jpitocch/genbio/immunenot.html 
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1.8.2.3. B-lymphocytes 
Producing antibodies against specific antigen of invading organism is primary duty of 
B-lymphocytes. Protective immunity require co-operation between T and B 
lymphocytes. Helper T-cell interaction required to produce high-affinity antibodies. 
Approximately 10
9
 B-cells produced daily. Mature B-cells carry antibodies (IgD and 
IgM) on their surface. There are about 10
7
 different specificities. Another important 
function of B-cells is to differentiate in Plasma cells (51). 
 
1.8.2.4. Plasma B cells 
Plasma cells are also known as “Antibody Factories”. These are the most abundant 
lymphoid cells with more than 80% presence in Intestinal Mucosa. Plasma cells from 
lamina propria are effector cells programmed to produce IgA and IgM. They are rich 
in endoplasmic reticulum responsible to produce large amount of antibodies (52, 53). 
 
1.8.2.5. Memory B cells 
Long lived plasma cells are known as Memory B-cells generate humoral immunity by 
continuous maintenance of serum antibody level. Rapid anamnestic antibody response 
that occurs after re-exposure to antigen is action of Memory B cells, which is 
important for eliminating the pathogen and toxic antigens. These cells also clear pre-
existing toxicity and maintain the pool of long-lived plasma cells in absence of 
pathogen. Memory B-cells originate from activated B-cells which are antigen specific 
produced during primary immune response. These cells are quick respondent in re-
exposure to that specific antigen (54, 55).  
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1.8.2.6. Antibody production 
Antibodies, therefore Immunoglobulins (Igs) constitute the gamma globulin part of 
the blood proteins. Gamma globulin constituents are: IgG-76%, IgA-15%, IgM-8%, 
IgD-1%, and IgE-0.002%. Among these, IgG is the predominant antibody for 
secondary response and poses an important defense against bacteria and viruses. IgA 
is the major immunoglobulin in colostrum, saliva, tears, and respiratory, intestinal and 
genital secretions. IgM is produced early in the primary response. IgE defends host 
against certain parasites and mediates anaphylaxis (50). 
 
1.8.2.7. Immunological memory 
Activation of lymphocytes during primary response generates long lived memory 
cells, which may survive for years after the infection. Memory cells represent an 
expanded pool of antigen-specific lymphocytes (52). 
In the course of infection, pathogen must reach to its target sites through blood and 
tissue fluids but in its way they are susceptible to different immune components. 
Immune system provides immediate or innate and acquired immunity that is more 
Figure 1.11: Clonal selection, expansion, proliferation and differentiation of B-
cells (52) 
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specific, rapid, efficient and regulated. The principal of immune system is to provide 
protection against foreign agents by distinguishing self from non-self (54). 
 
1.8.2.8. Primary response 
After encounter of an antigen, antibodies are detectable in the serum after a lag phase, 
of 5-7 days. A small clone of B-cells and plasma cells specific for that invading 
antigen is formed depending on the nature and dose of the antigen and the route of 
administration. The serum antibody concentration continues to rise for several weeks, 
as primary response of infection as innate immunity and then starts to decline. The 
first antibodies to appear are IgM, followed by IgA or IgG. IgM levels decline earlier 
than IgG levels.  (55). 
 
1.8.2.9. Secondary Response 
There are cells of at least three stages of maturation: naïve cells, effectors cells and 
memory cells in peripheral lymphoid organs. During primary response some cells are 
stimulated to proliferate and differentiate into effectors cells, which are actively 
engaged in making a response (effectors B cells secrete antibody, while effectors T 
cells kill infected cells or help other cells fight the infection), some naïve cells are 
stimulated to multiply and differentiate into memory cells named as clonal expansion, 
that are not themselves engaged in a response but are more easily and more quickly 
induced to become effectors cells by a later encounter with the same antigen known as 
secondary response as adaptive immunity (57, 58). Secondary immune response 
(second or subsequent exposure to an antigen) is not only faster but produces antibody 
with up to a 10,000 fold increased binding affinity. Re-exposure to antigen is most 
likely to cause clonal expansion of memory cells to produce the highest affinity 
antibody. Although the early systemic response is of IgM, subsequent challenges, 
tends to induce a switch to IgG antibodies. Also, since many if not all of the memory 
B cells will have switched to IgG (IgA or IgE) production, IgG is produced earlier in 
a secondary response (56).  
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1.9. Immunologic response against Vibrio cholerae 
The mechanism of immunity against Vibrio cholerae infection is not clearly 
understood yet. Immunologic response following infection can be classified into 
several types and classes. 
 
1.9.1. First line of defense 
Innate immunity refers to body‟s pre-existing protection mechanism against invading 
agents, which include physical barriers (the skin and mucosal surfaces) and chemical 
substances (mostly proteins) that neutralize microorganisms and other foreign 
particle. Following infection by both Vibrio cholerae O1 and O139, innate cells are 
activated and mediators remain elevated at the mucosal surface. Mucosal mast cells 
(MMC) play a crucial defense against immediate infection. These cells are activated 
by binding with of IL-3 and Stem Cell Factors (SCF), which produced from T-cells 
and epithelial cells (59). Mast cells produce IL-4 that is an early response cytokine to 
activate Th-cells. Presence of IL-3 and SCF in duodenal secretion explains MMC 
Figure 1.12: Primary and secondary immune response (52) 
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activation and production of Th-2 type cytokines IL-4 and IL-5 (59) in adult cholera 
patients. As primary host defense, mobilization of neutrophil polymorph is stimulated 
by mast cell derived TNF-α at the site of infection. In acute stage of cholera increased 
level of TNF-α, suggest that it may act as an early response cytokine to up regulate 
Polymorpho Nuclear (PMN) and initiate bactericidal proteins. Mast cell produced 
leukotriene (LT) LTB-4 and LTC-4 are rich in intestinal secretion following infection 
indicates migration and recruitment of neutrophils (60, 61). Mast cells are found with 
increased level of lipid bodies suggesting increased production of arachidonic acid 
meatbolites (66). Arachidonic acid Prostaglandin E2 found to be increased in cholera 
infection (61, 62). Increased level of leucocytes, including PMN, found in gut (62, 
63). Among others bactericidal proteins- lactoferrin, MPO, as well- defensin were 
also elevated during the acute stage, further highlighting the functional role of PMN 
in cholera. Not only neutrophils but eosinophils also remain elevated in acute cholera 
cases which necessary to activate mast cells to produce IL-5 (64, 65). Innate 
immunity also rises in rectal areas in patients with natural cholera infection (66). 
 
1.9.2. Serum antibody responses  
Vibrio cholerae being a non-invasive, serological immunity against it is very 
important.  Serological immune response varies with day points in both naturally 
infected patient and vaccinated individuals. Signiﬁcant increases of LPS-speciﬁc IgA 
and IgG antibody levels were found in duodenal extracts on day 30 and decreased to 
baseline by day 180. LPS-speciﬁc IgA in plasma remained elevated longer. Levels of 
mucosal CTB antibodies also peaked on day 30, but were signiﬁcant only for IgG 
(67). In duodenal fluids, mucosal secretory IgA (sIgA) antibodies were detected but 
these also returned to baseline within 6 months (67). 
 
1.9.3. Vibriocidal responses 
Vibriocidal is an assay that measures the ability of serum antibodies to lyse V. 
cholerae in the presence of complement. This is the best-characterized marker of 
protective immunity to cholera is the plasma, a complement-dependent bactericidal 
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antibody that increases with age in areas in which cholera is endemic. But vibriocidal 
antibodies directly mediate protection is very unlikely because there is no threshold 
vibriocidal-antibody titer at which protection against cholera is achieved (67, 68). 
Vibriocidal antibodies (mainly, but not entirely directed against LPS) have been 
inversely correlated with susceptibility to infection (69, 70). The vibriocidal-antibody 
titer peaked by day 7 and remained signiﬁcantly elevated through day 90 before 
declining to baseline levels at day 180 (67). 
 
1.9.4. Antibody secreting Cell (ASC) responses 
Individuals infected with V. cholerae developed IgA  ASCs specific for LPS and 
CTB, which peaked 7 days after the onset of disease (40, 73) and expressed the gut-
homing receptors α4β7 (74). Circulating IgA ASCs are typical markers of mucosal 
priming after enteric infection. Mucosal LPS-specific IgA ASCs were demonstrated 
in duodenal biopsy specimens from cholera-infected patients. The cells remained 
detectable for  6 months, even in the absence of detectable anti-LPS IgA in secretions. 
A signiﬁcant CTB-speciﬁc IgA levels were found in duodenal extracts on day 30. 
These cells may resume antibody production when appropriately stimulated (67). 
 
1.9.5. Memory B cell responses 
Protective immunity mediators against cholera are yet to be known, but memory B-
cells response may play a central role in facilitating long-term and anamnestic 
responses against Vibrio cholerae. It was reported that individuals with natural 
cholera developed plasma anti-cholera toxin B subunit (CtxB) and lipopolysaccharide 
(LPS) IgA responses, which returned to baseline by 1 year of follow-up (40). Again 
CtxB-speciﬁc IgG memory B cell responses are detectable in the circulation at least 
180 days following V. cholerae O1 infection and remain measurable even after  serum 
antibody titers have declined to considerably lower levels (71). Dukoral vaccinated 
individuals showed IgA and IgG memory B cells responses to CTB for 1 to 6 months 
while there was no response to LPS (40). But IgG memory B cells responses against 
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V. cholerae O1 LPS and protection against infection in household contacts of cholera 
patients was found (72). 
 
1.10. General objectives of the study 
To assess whether natural infections in cholera endemic areas can provide longer term 
protective immunity for long and the role of memory B cells in this regard. 
 
1.11. Specific objectives of the study 
A. To investigate antigen specific memory B cell proliferation and its persistency 
and it‟s potential to generate protective immunity in naturally infected cholera 
patients. 
B. To compare circulating memory B cell specific to OSP and LPS up to day 
180.   
Methodology
Chapter 2
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2.1. Place of study 
The study was carried out in the Laboratory Sciences Division (LSD), International 
Centre for Diarrhoeal Diseases and Research, Bangladesh.  All the patients were 
enrolled from icddr,b Hospital. The study was approved by the Research Review 
Committee (RRC) and Ethical Review Committee (ERC) of icddr,b. 
 
2.2. Study participants 
Participant were about 60 enrolled V. cholerae positive patients at icddr,b hospital. 
Written informed consent for the study was obtained from them following infection. 
Blood samples were collected during acute infection (the second day of 
hospitalization) and again on days 7, 30, 90 and 180 following illness onset. For each 
day point, ELISA for plasma IgG, IgA and IgM antibodies to OSP, LPS and CTB and 
also vibriocidal assay were performed. OSP, LPS and CTB specific IgA, IgG and IgM 
antibodies were assayed on day 2, 30, 90, 180 in Memory B cell culture supernatant. 
 
2.3. Study design and sample collection 
Admitted patients with characteristic rice watery appearance stools were screened by 
dark-field microscopy to observe darting movement of V. cholerae by its flagella. To 
confirm cholera infection followed by serotype and biotype test by specific antibody 
after culturing in TTGA plates (75). Blood had drawn from confirmed cholera 
positive patients at day points 2, 7, 30, 60 and 180 and separated into Plasma and 
PBMC. Vibriocidal assay and ELISA for specific antibodies were performed for 
plasma of each day points. 
 Figure 2.1: Blood Sample collection at different day points 
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Collected blood sample at 
Day 2/30/90/180 
Plasma PBMCs isolated from blood, 
washed and suspended in media 
ELISA for specific 
antibody 
Vibriocidal assay 
Polyclonal stimulation: With 
optimized mix of mitogens: 
PWM, CpG, SAC 
No Stimulation: Negative 
control; Media only 
ELISPOT to quantify 
antigen-specific IgG, IgA 
and IgM memory B-cells 
PBMCs plated on 24 well 
plates in 1 mL media at 
5x105 cells per well 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 2.2: Assays with blood sample 
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2.4. Laboratory Methods 
2.4.1. V. cholerae positive patients are confirmed by three different tests 
 
 
 
 
 
 
 
2.4.1.1.Dark field microscopy to detect V. cholerae 
Stool from patients with characteristic rice watery appearance were observed using 
dark field microscopy for motility of V. choleare that confirms vibrios infection. The 
movement is rapid to- and fro-, which is characteristic and unique to the organisms of 
this genus “Vibrio” (77). By using this property V. cholerae is easily detected without 
help of any stain. For this quick technique, one drop of stool sample is dropped on a 
clean slide and cover slip applied on it. Emulsion oil was applied on the lens to aid the 
visibility. Then the slide was observed at 40X magnification (Figure 2.4). Stool 
samples with motility are defined as DF
+
 and enrolled as cholera positive patient (77). 
 
 
 
 
 
 
Figure 2.3: Serological confirmation of V. cholerae infected patients 
Serological 
confirmation 
using 
monoclonal 
antibody 
Streaked on 
TTGA plates to 
culture 
Dark field 
Microscopy to 
detect motile V. 
cholerae 
Figure 2.4: Vibrio cholerae in dark field microscopy 
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2.4.1.2.Serological detection of Vibrio cholerae     
Antibodies were used to inhibit motility in stool sample, which confirms the 
serogroup of the pathogen. Stool specimens from the DF
+
 patients were streaked on 
TTGA (taurocholate-tellurite-gelatin agar) plate. DF
+
 stool makes a transparent 
colony with a dark zone of potassium tellurite on TTGA plate. 
 
 
 
 
 
 
 
 
 
 
V. cholerae O1 or V. cholerae O139-specific mouse antisera were used for serotyping. 
Mouse anti-serum was raised against V. cholerae O1 for both Inaba and Ogawa 
serotypes. A slide was taken and divided into three blocks and marked. Then three 
types of antisera (V. cholerae O1 Ogawa, V. cholerae O1 Inaba and V. cholerae 
O139-specific mouse-rabbit antisera) were dropped on each block of the slide (Figure 
18). Bacterial colony from the TTGA plate was applied on each block of the slide. 
Slide was observed with bright light for agglutination in blocks. The occurrence of 
clear agglutination within 2 minutes was considered a positive reaction. Only V. 
cholerae O1 reacting samples Ogawa were enrolled in this study. 
Figure 2.5: Vibrio cholerae colonies in TTGA plate 
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2.4.2. Isolation of Peripheral Blood Mononuclear Cells (PBMC) 
a. Heparinized venous blood was diluted with equal volume of Phosphate Buffered 
Saline (PBS, 10 mM, pH = 7.2) in 50 mL Falcon tubes. 
b. Diluted blood was carefully added to the volume of Ficoll-Isopaque (Pharmacia, 
Uppsala, Sweden) (in a 1:1 ratio of undiluted blood) without disturbing the Ficoll 
layer. Hence, two distinct layers were maintained. 
c. The tubes were centrifuged at 700 g for 30 minute at 25:C (in a Sorvall® 
Legend™ XRT super speed centrifuge) 
d. After centrifugation, PBMCs remained at the interface of plasma and Ficoll. 
RBCs and other cell debris were precipitated at the bottom of the tube. The 
mononuclear cells were then removed from the top of the Ficoll layer carefully 
with a Pasteur pipette. 
e. The PBMCs were washed once in PBS at 500 g for 15 minute at 25:C. 
f. The PBMCs were resuspended in 10 ml of PBS. 25μl of cell suspension was 
collected into an eppendorf tube (25μl cell suspension with 25μl trypan blue) and 
Figure 2.6: Serological detection of V. cholerae O1, Coagulation was seen at the 
first portion of the slide indicates antisera containing anti Ogawa antibody cross 
links V. cholerae and gives a spotted colour. 
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the MNCs were counted in a haemocytometer while the resuspended PBMCs 
were washed for the second time at 500 x g for 5 minute at 25:C.  
g. After the second wash, cells were resuspended in RPMI Complete medium such 
that 100 µL contained 1×10
5
 cells (e.g. 1 mL for 10 million cells). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.7: Isolation of PBMC by density gradient centrifugation on 
Ficoll-Isopaque 
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2.4.3. Antigen preparation 
To measure immunological responses V. cholerae specific purified LPS, OSP and 
rCTB were used as antigens. LPS was obtained from V. cholerae O1, Ogawa (strain 
X-25049) by protein denaturation by hot phenol-water extraction (78, 79) followed by 
enzymatic treatment (DNase, RNase and protease), and ultracentrifugation (100,000 × 
g for 3 h) (80). OSP was recovered by acid hydrolysis of LPS, generating OSP 
attached to core oligosaccharide (OSPc) (78, 79, 80) and same followed to generate 
OSPc:BSA conjugates. To facilitate binding of OSP to immunological plates, and to 
permit display of OSP in a sun-burst pattern consistent with single point attachment 
similar to that occurring on wild type V. cholerae, we assessed immune responses 
targeting OSP using OSPc:BSA (henceforth referred to as OSP in immunonologic 
assays).  To assess responses targeting CTB, we used recombinant antigen supplied 
by Professor A. M. Svennerholm, Gothenburg University, Sweden. 
 
2.4.4. Determination of OSP, LPS and CT specific memory B cell 
responses by ELISPOT assay 
2.4.4.1. Overview of ELISPOT assay 
The Enzyme-Linked ImmunoSpot (ELISPOT) assay is a very sensitive immunoassay 
which measures the frequency of antibody-secreting cells at the single-cell level. Cells 
are cultured on a nitro cellulose membrane surface coated with a specific capture 
antibody in the presence or absence of stimuli. Antibodies which are secreted by the 
cells will be captured by the specific antibodies on the surface. 
After incubation time, cells are removed by washing and the secreted molecule is 
detected by using a substrate (BCIP/NBT/AEC) with a precipitating rather than a 
soluble product, the end result is seen as visible spots on the surface where each spot 
corresponds to an antibody-secreting cell. 
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Spots seen under stereo 
microscope in a well-
developed plate 
Figure 2.8: ELISPOT Assay. (a) Red spots correspond to IgA or IgM and 
(b) Blue spots corresponds to IgG. 
http://www.immunospot.com/index.php?id=514 
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2.4.4.2. ELISPOT assay protocol for Memory B cell culture 
Coating of plates 
I. Nitrocellulose wells were coated with 
 Affinipure Goat anti-human IgG ((Jackson Immunology Research Cat 109-
005-097) ) at 5.0 µg/ml in PBS for the total – Immunoglobulin plate 
(positive control)  
 KLH Keyhole Limpet Hemocyanin (KLH) (Pierce Biotechnology, 
Rockford, IL), at 2.5 µg/ml in PBS for negative control and 
 OSPc:BSA OSP, at 10.0 µg/ml in PBS. 
 100 µl of GM1 (Ganglioside Monophosphate) (Sigma, cat#G-7641), at 3 
nmol/ml in PBS followed by r recombinant Cholera Toxin B subunit (rCTB) 
at 2.5 µg/ml 
 
LPS (Ogawa) Plate coating  
a. 50 μl of poly-L-Lysine solution (conc.10μg/ml PBS) was added to each 
well and kept at room temperature for at least 30 min. 
b. The wells were decanted and immediately 50 μl bacterial suspension 
(whole cell at conc. of 5.5x10
9
) or LPS (25 μg/ml in PBS) 50 μl was added 
to each well. 
c. The plates were centrifuged at 2000 rpm for 5 min. 
d. The content (nothing is left actually) was not decanted and gently 50 μl of 
0.5% gluteraldehyde was added. (carried out inside hood) [Gluteraldehyde 
is toxic, so gloves is recommended] 
e. Kept at room temperature for 15 min. 
f. The plate was washed twice with PBS (gently). 
g. 200 μl 0.1 % BSA in 0.1 M glycine was added to each well. 
h. Kept at room temperature for 30 min. 
i. Washed twice with PBS. 
j. These plates were then ready to use. 
k. To store the plates, 200 μl 0.1% BSA-PBS was added to each well and kept 
at –20 ºC 
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II. Plates were incubated at 4:C overnight. 
III. The GM1 coating buffer was decanted and the CT plate was washed 23 times 
with PBS. Excessive liquid was removed. 100µl of recombinant cholera toxin 
B-subunit (rCTB) (2.5µg/ ml in PBS) was added to each of the GM1 coated 
wells and PBS to the other wells (100µl/well). The plates were then incubated 
for one hour at 37:C. 
 
Blocking 
a. All the plates were washed twice gently with PBS only. 
b. Next they were blocked with 200 µl RPMI complete media per well at 37:C for 
2 hours. 
 
Memory B cell culture of collected blood sample 
Reagents for stimulation media 
 Crude Pokeweed Mitogen extract (1:100,000 dilutions) 
 Staphylococcus Aureas Cowan (SAC), fixed. (Sigma Cat #P7155). (1:10000 
dilutions) 
 CpG oligonucleotide. [TCGTCGTTTTGTGTTTTGTCGTT from operon] (6 
µg/ml) 
 
Memory B cell culture 
a. Culture wells were divided into unstimulated and stimulated wells.  
b. To each of these wells, 5 x 105 peripheral blood mononuclear cells were added. 
Sterility was critical. 
c. 1 mL of unstimulation culture media/well and 1 mL stimulation culture 
media/well were added to respective culture wells using sterile technique. 
Sterility was very critical in this particular step. 
d. These culture plates were incubated in 5% CO2 at 37:C for 5-6 days. 
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Culture cell harvest 
a. After 5-6 days of proliferation, culture cells were collected in eppendorf tubes 
from each culture well. 
b. All the eppendorf tubes were centrifuged at 2500 rpm for 7 minutes. 
c. Washed cells with PBS again centrifuged at 2500 rpm for 7 min. 
d. Finally, cell pellet was resuspended in 200 µL RPMI complete media which 
contains approximately 5×10
5
 peripheral blood mononuclear cells. 
 
Cell loading and developing 
a. The blocking solution was decanted. From each culture well, 20% of cells were 
used for total Ig’s ELISPOT, while 80% were used for antigen specific memory 
B cell ELISPOT. Keeping this in mind, in the LPS, CT and OSP-plates, 40 µL 
of fresh RPMI complete media was added to the first row and 160 µL to 
subsequent rows for dilution. For the Total Ig’s plate, 160 µL of fresh media 
was added to the first row and 180 µL to subsequent diluting rows. 
b. 160 µL of the re-suspended cells were added to each well for the neat well for 
LPS, CT and OSP- specific wells and remaining 40 µL of resuspended cells 
were added to the first row of total Ig’s plate. 
c. Three 10 x dilutions of the total Ig’s wells (transferring 20 µL), and a 5 x 
dilutions of the LPS, OSP and CT wells (transferring 40 µL) were carried out. 
The plates were incubated with cells for 5 hours at 37:C in a CO2 (5%) 
incubator. 
d. Next the cells were decanted and the plates were washed 5 times with PBS-
Tween (0.05%) and 3 times with PBS. Excess liquid was shaken off in such a 
manner so that the nitrocellulose membrane does not become dry. 
e. Anti-human IgA-HRP, anti-human IgG-AP and anti-human IgM-HRP at 1:500 
were diluted in 1% FBS in PBS-Tween 0.05%. To each well 100 µL was added. 
All plates were incubated overnight at 4:C. The liquid was decanted and plates 
were washed 5 times with PBS-Tween and 3 times with PBS. 
f. HRP chromogen/substrate, AEC/H2O2, was prepared in advance up to two 
weeks and stored at 4:C. (AEC/H2O2 preparation: 10 mg of AEC in 1 mL of 
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DMF
+
 29 mL of Na-acetate then filtered through 0.2 µM). 5µL of 30% H2O2 
was added to 10 mL of AEC solution and vortexed well. 100µL of the 
chromogen/substrate was added to every well and the color reaction monitored 
immediately. 
g. When the spots were clearly visible, the reaction was stopped by washing the 
plates repeatedly with tap water. 
h. Plates were then soaked in tap water for 30 min before allowing them to dry in 
room temperature. 
i. The spots were counted under low-magnification and the plates were stored 
away from light to count later. 
j. Each red spot represented an IgA secreting cell and every blue spot indicated an 
IgG secreting cell in anti-human IgA-HRP conjugate and anti-human IgG-HRP 
conjugate added wells respectively while each red spot represented an IgM 
secreting cell in anti-human IgA-HRP conjugate added wells. 
k. Data was evaluated as antigen specific IgG/A/M memory B cell divided by total 
IgG/A/M memory B cell and per 10
6
 PBMC. And the results were expressed as 
percentage. 
l. Appropriate stimulation of PBMC in this assay was defined as a ≥ 4 fold 
increase in the number of total Ig memory cells following stimulation as 
compared to the unstimulated cells. This definition included approximately 90% 
of all stimulated cultures for IgG, IgA and IgM memory cells. 
 
2.4.5. ELISA for detection of IgA, IgG and IgM antibodies against 
Lipopolysaccharide (LPS), O-specific polysaccharide (OSP) and 
Cholera Toxin (CT) in plasma samples 
2.4.5.1. Enzyme-Linked Immunosorbent Assay (ELISA) Principle 
The ELISA is a specific and highly sensitive method for quantification of antibodies 
and other analytes in solution. The set-up consists of a specific antigen, coated to a 
microtiter plate, which is able to capture the protein of interest. After addition of the 
sample, the specific antigen on the plate will capture. A secondary monoclonal 
antibody, used for detection, binds a different epitope on the primary antibody. The 
detection antibody is conjugated with Horseradish peroxidase. Any unbound reagents 
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are washed away. When substrate is added, a color reaction will develop which is 
proportional to the amount of protein bound. The concentration of protein in the 
sample is determined by comparison with a standard curve with known concentrations 
of protein. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.9: Principle of Enzyme-Linked Immunosorbent Assay (ELISA) 
Measurement at 
450nm for 5min 
(Kinetic) 
Substrate 
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2.4.5.2. ELISA to detect IgA, IgG and IgM antibodies against 
Lipopolysaccharide (LPS) and O-Specific Polysaccharide (OSP) in 
plasma 
Coating  
The ELISA plates (Nunc F, Denmark) were coated with V. cholerae LPS about 
100µL/well at a concentration of 2.5 µg/ml in PBS (pH 7.2-7.4) and OSPc:BSA at a 
concentration of 1µg/ml in carbonate buffer (pH 9.8). The plates were then incubated 
at room temperature for overnight. Following overnight incubation, the ELISA plates 
could be stored at 4:C for a week. 
 
Blocking  
The LPS and OSP-coated plates were washed thrice with PBS and blocked with 1.0% 
Bovine Serum Albumin in PBS (BSA-PBS), 200 µL/well for 45 minutes at 37:C. 
 
Loading of Samples and Plate developing  
a. The plates were washed 3 times with PBS-Tween (0.05 %) and once with PBS. 
b. The plasma samples (initial dilution 1:50 for IgA, IgG & IgM) diluted in 0.1% 
BSA-PBS containing 0.05% Tween were loaded 100 μl per well of the plates.  
c. The plates were incubated at 37:C for 90 minutes. 
d. The plates were washed 3 times with PBS-Tween (0.05 %) and once with PBS. 
e. The horseradish peroxidase (HRP) conjugated rabbit anti-human IgA, IgG and 
IgM (Jackson Immune Research Laboratories Inc.) were diluted in 0.1% BSA-
PBS Tween and added 100 μl per well. 
f. The plates were incubated for 90 minutes at 37:C. 
g. The plates were washed 3 times with PBS- Tween (0.05 %) and once with PBS. 
h. The plates were developed with the substrate orthophenylene diamine (OPD) as  
100μl/well, prepared by dissolving 10 mg of OPD in 10 ml of 0.1 M sodium 
citrate buffer, (pH 4.5) to which was added 4 μl of 0.1 % H2O2 immediately 
before use. 
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i. The plates were read kinetically at 450 nm for five minutes. The maximal rate of 
change in optical density in milli absorbance units per minute was normalized 
across plates by calculating the ratio of the test sample to a standard of pooled 
convalescent-phase serum from previously-infected cholera patients, which was 
added as a positive control on each plate. For the LPS and OSP antigen, 
individuals with a ≥2-fold increase in antibody titer one or three weeks post 
infection or vaccination were considered as responders. 
 
2.4.5.3.ELISA to detect IgA, IgG and IgM antibodies against Cholera Toxin (CT) 
B subunit 
Coating  
The ELISA plates (Nunc F, Denmark) were coated with 100 µL/well of GM1 (Sigma, 
cat#G-7641) at a concentration of 0.3 nmol/mL or 0.5 µg/mL in PBS. The plates were 
then incubated at room temperature for overnight. Following overnight incubation, the 
ELISA plates were stored at 4:C up to 2 weeks for further use. 
 
Blocking 
The GM1-coated plates were washed twice with PBS and blocked with 1% Bovine 
Serum Albumin in PBS (BSA-PBS), 200µL/well and incubated for 30 minutes at 
37:C. 
 
Loading of Samples and Plate developing 
a. The plates were washed thrice with PBS-0.05% Tween and once with PBS. 
b. The purified rCTB (0.5µg/ml in PBS) diluted in 0.1% BSA-PBS were added, 
100µL per well and incubated for 60 min at 37:C. 
c. The plates were washed 3 times with PBS - Tween (0.05 %) and once with PBS. 
d. The plasma samples (initial dilution 1:100 for IgA, IgG & IgM) diluted in 0.1% 
BSA-PBS containing 0.05% Tween were loaded 100 μl per well of the plates. 
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e. The plates were incubated at 37:C for 90 minutes. 
f. The plates were washed 3 times with PBS- Tween (0.05 %) and once with PBS. 
g. The horseradish peroxidase (HRP) conjugated rabbit anti-human IgA, anti-
human IgG and goat anti-human IgM (Jackson ImmunResearch Laboratories 
Inc.) were diluted in 0.1% BSA-PBS Tween and added 100 μl per well. 
h. The plates were incubated for 90 min at 37:C. 
i. The plates were washed 3 times with PBS- Tween (0.05 %) and once with PBS. 
j. The plates were developed with the substrate orthophenylene diamine (OPD)-
100 μl/well, prepared by dissolving 10 mg of OPD in 10 ml of 0.1 M sodium 
citrate buffer, (pH 4.5) to which was added 4 μl of 0.1 % H2O2 immediately 
before use. 
k. The plates were read kinetically at 450 nm for five minutes. The maximal rate of 
change in optical density in milli absorbance units per minute was normalized 
across plates by calculating the ratio of the test sample to a standard of pooled 
convalescent-phase serum from previously-infected cholera patients, which was 
added as a positive control on each plate. For the CTB antigen, individuals with 
a ≥2-fold increase in antibody titer one or three weeks post infections were 
considered as responders. 
 
2.4.6. Vibriocidal assay 
Vibriocidal antibody assays were performed using guinea pig complement and with V. 
cholerae O1 Ogawa (X-25049) as the target organism. Vibriocidal titer was defined 
as the reciprocal of the highest dilution resulting in >50% reduction of the optical 
density when compared to that of control wells without serum. Individuals showing a 
≥4-fold increase in vibriocidal responses one or three weeks post infection were 
considered responders. 
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Procedure 
a. V. cholerae O1 (strain X-25049 El Tor Ogawa) were cultured overnight on 
blood agar plates at 37:C. 
b. A loop full of bacteria from the plates was inoculated in 15 ml BHI (brain-heart 
infusion)-medium in a conical flask with cotton plug. This was incubated on a 
shaker at 37:C for 3-4 hours. 
c. The culture was centrifuged at 3000 rpm for 10 minutes and the supernatant was 
discarded. The sediment was resuspended in sterile saline. 
d. This was again centrifuged for another 8-10 minutes. The pellet was 
resuspended in sterile saline. 
e. Bacterial concentration was adjusted by spectrophotometer at 600 nm. For V. 
cholerae O1, OD was adjusted at 0.3. 
f. Heat-inactivated (56:C, 30 minutes) sera were diluted 2-fold in sterile saline in 
flat-bottom microtiter plates (Nunc, F) as follows: 
 25 μl of cold saline was dispensed in all wells except column no. 2. 
 45 μl of cold saline and 5 μl of test sera were dispensed in column no. 2. 
g. The sera was serially diluted (initial dilution 1:10) 2-fold by using a multi-
channel dispenser. The dilution was accomplished by mixing the solution in 
column #2, aspirating 25 μl and dispensing and mixing the sample in column #3 
and so on, till column #12 (this equals to 1:10240). The last 25 μl was discarded 
from the last well on each row. The plates were kept at 4:C (on ice) until used. 
h. The indicator (bacteria-complement-saline mixture) was prepared. The 
composition for each plate is as follows: 
 Sterile Saline Bacteria Complement 
V. Cholerae 01 (X25049) 2.55 ml 150 µl 300 µl 
 
i. The indicator was used immediately after preparation. 
j. 25 μl of the indicator was added to all wells except wells in row A, B, C and D 
in column #1. The plate was incubated on a shaker at 37:C for 1 hour (50 
revolutions /min). 
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k. 150 μl BHI was added to each well. This was incubated for another 3-4 hours at 
37:C without shaking. The plates were read visually and spectrophotometrically. 
The absorbance for control wells should reach 0.20 to 0.28 at 595 nm. 
Vibriocidal antibody titer is defined as the reciprocal of the highest serum 
dilution resulting in greater than 50% OD reduction when compared to the OD 
of control wells without serum. 
 
2.5. Statistical analysis 
Comparisons of immunologic responses were tested for significance among the 
groups using Mann Whitney Rank-sum test. All reported P values are two-tailed, with 
a cutoff of P ≤ 0.05 considered a threshold for statistical significance. All the analyses 
were performed on GraphPad Prism 5.0 (GraphPad Software, Inc.,La Jolla, CA). 
 
 
 
Results
Chapter 3
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3.1. Study subjects 
A total of 60 cholera patients were enrolled for the study and 87% of the patients 
completed the follow up to day 180. Among them, 66.7% were male. Median of 
patients’ ages was 13 years. All the patients were Vibrio cholerae O1 ogawa serotype 
infected patients. The demographic characteristics of the patients were presented in 
table 3.1.  
 
 
 
Characteristics Frequency 
Median of ages 13 years 
Sex of patient 
Male 20 
N=60 
Female 40 
Blood group of patients 
O+ ve 19 (31.6%) 
O- ve 1 (1.7%) 
A+ ve 15 (25%) 
B+ ve 20 (33.3%) 
B- ve 1 (1.7%) 
AB+ ve 4 (6.7%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.1: Demographic and serological characteristics of the study subjects 
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3.2. Vibriocidal response 
Vibriocidal antibody response specific to V. cholerae 01 ogawa were measured at 
days 2, 7, 30, 90, 180. 
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All patients presented strong vibriocidal response on day 7 and represented at least 
four fold increases in vibriocidal titer compared to baseline; and remained elevated up 
to day 180. The geometric mean (GM) of vibriocidal titer on day 2 was 28.46 (95% 
confidence interval [CI], 18.30 to 44.25). The day 7 vibriocidal titer (GM, 2100; 95% 
CI, 1459 to 3023; P<0.0001) in the patients were significantly higher than the titer on 
day 2. On day 30 and day 90 the geometric mean were 593.4 (95% CI, 437.2 to 805.4; 
P<0.0001) and 204.5 (95% CI, 150.9 to 277.2; P<0.0001) respectively and showed a 
lowest GM of 118.2 (95% CI, 81.13 to 172.2; P=0.0007) on day 180 during the 
follow up period. The titer waned down continuously after day 7 however it was 
significantly higher when compared to day 2 vibriocidal responses. Responder 
frequency was found highest on day 7 (96%) as well, while the lowest was on day 180 
(67%) (Figure 3.1). 
Figure 3.1: Mean serum Vibriocidal antibody response with (±SEM) standard 
error bars. An asterisk indicates significant difference compared to baseline values 
(P<0.05). 
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3.3. Anti-OSP and Anti-LPS specific antibody response in plasma 
and serum 
ELISA was performed to study Anti-OSP and Anti-LPS specific antibody response 
and two fold increase in responses were considered as respondent.  
 
3.3.1. Anti-OSP and Anti-LPS specific IgA antibody response 
Compared to baseline responses, anti-OSP specific IgA plasma antibody response was 
significantly increased on day 7 with GM 65.53 (95% CI, 42.53 to 101.0; P<0.0001) 
with response rate of 74%. Response also increased on day 30 (GM, 26.88; 95% CI 
18.84 to 38.33; P<0.0001) and 90 (GM, 16.12; 95% of CI 12.79 to 20.33, P=0.0015), 
but showed a decreased response rate of 52% to 46% in the patients. The lowest 
response rate was 39%, and seen on d180 (GM, 10.63; 95% CI, 8.84 to 13.32; 
P=0.1654) (Figure 3.2). 
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Figure 3.2: Mean plasma Anti-OSP specific IgA antibody response (with 
standard error). An asterisk indicates significant difference compared to baseline 
values (P<0.05). 
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Anti-LPS IgA antibody response was significantly developed on day 7, 30, 90 and 
180, when compared to baseline responses. Highest result was achieved on day 7 
(GM, 57.71; 95% CI, 37.43 to 88.96; P<0.0001), day 30 (GM, 22.43; 95% CI 16.49 to 
30.52; P<0.0001) and responses rate were 75% and 60% respectively. Response on 
day 90 (GM, 19.12; 95% CI, 15.59 to 23.46; P<0.0001) and day 180 (GM, 15.15; 
95% CI, 12.42 to 18.42; P=0.0032) were also significant with decreasing response 
rate seen in 51% to 38% of patients (Figure 3.3). 
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Figure 3.3: Mean plasma Anti-LPS specific IgA antibody response (with 
standard error). An asterisk indicates significant difference compared to baseline 
values (P<0.05). 
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3.3.2. Anti-OSP and Anti-LPS specific IgG antibody response 
Anti-OSP specific IgG antibody response significantly increased on day 7 and 
persisted up to day 180 (P<0.0001). The geometric mean titre (GM) was maximum at 
day 7 (100.4, 95% CI, 80.75 to 124.9) with maximum response in 76% of patients. 
Gradually decreased responses were observed on following days 30 (GM, 83.28; 95% 
CI, 66.71 to 104; 54%), 90 (GM, 64.0; 95% CI, 52.67 to 77.93; 65%) and 180 (GM, 
49.29, 95% CI, 42.28 to 57.46; 46%) (Figure 3.4). 
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IgG antibody response specific to LPS was also found to be elevated. The showed 
results like anti-OSP IgG. Compared to baseline response significant OSP-IgG 
responses (P<0.0001) on 7, 30, 90 and 180 were observed with response in 64%, 
Figure 3.4: Mean plasma Anti-OSP specific IgG antibody response (with 
standard error). An asterisk indicates significant difference compared to baseline 
values (P<0.05). 
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56%, 43% and 45% on day 7 in patients. A maximum GM of 88.35 was obtained on 
day 7 (95% CI, 73.14 to 106.7) which decrease gradually at different study days, i.e. 
on day 30 (GM, 72.49; 95% CI, 61.11 to 85.98), day 90 (GM, 61.25; 95% CI, 53.34 
to 70.33) and day 180 (GM, 57.59, 95% of CI, 51.58 to 64.29) (Figure 3.5). 
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Figure 3.5: Mean plasma Anti-LPS specific IgG antibody response (with 
standard error). An asterisk indicates significant difference compared to baseline 
values (P<0.05). 
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3.3.3. Anti-OSP and Anti-LPS specific IgM antibody response 
Anti-OSP specific IgM response was most significant (P<0.0001) on day 7 and day 
30. Maximum GM 157.5 was obtained on day 7 (95% CI 123.1 to 201.4) with 
maximum response rate in 71% of patients. Although response was significant on all 
day points it waned during convalescence. The same was observed for response at the 
different time points i.e. day 30 (GM, 96.14; 95% CI, 77.70 to 119.0; 50%), day 90 
(GM, 65.10; 95% CI, 53.78 to 78.81; 40%) and day 180 (GM, 56.96; 95% CI, 47.20 
to 68.75; 35%) (Figure 3.6).  
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Figure 3.6: Mean plasma Anti-OSP specific IgM antibody response (with 
standard error). An asterisk indicates significant difference compared to baseline 
values (P<0.05). 
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Anti-LPS specific IgM responses were significant (P<0.0001) for the all study days. 
The maximum response was 73% with highest GM of 139.3 on day 7 (95% CI, 117.9 
to 164.4). The GM for following day points were almost consistent having 94.98, 
75.49 and 76.60 respectively with responses of 53% on day 30 (95% CI, 81.16 to 
111.2), 42% on day 90 (95% CI, 61.65 to 92.42) and 38% on day 180 (95% CI, 62.80 
to 93.45) (Figure 3.7). 
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Figure 3.7: Mean plasma Anti-LPS specific IgM antibody response (with 
standard error). An asterisk indicates significant difference compared to baseline 
values (P<0.05). 
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3.4. Anti-CtxB specific IgA and IgG antibody response in blood 
plasma and serum 
IgA antibody response specific to rCtxB was significant increased throughout the 
whole study day points, with a peak response on day 7 (GM 32.76; 95% CI 25.29 to 
42.44; P<0.0001) with 93% response rate. Although responses waned in different 
time points, it was significantly high on day 30 (67%; GM 11.24; 95% CI 8.653 to 
14.63). The responses were also significantly on day 90 (GM 6.600; 95% CI 5.287 to 
8.239; P=0.0009) and day 180 (GM 5.317; 95% CI 4.287 to 6.693; P=0.0230) (Figure 
3.8). 
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Figure 3.8: Mean plasma Anti-CtxB specific IgA antibody response (with 
standard error). An asterisk indicates significant difference compared to baseline 
values (P<0.05). 
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CT IgG
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Unlike the CT-IgA response, the CT-IgG response peaked on day 30 (GM 58.39; 95% 
CI 49.56 to 68.79%; P<0.0001) with 91% responders. Responses on all study days 
showed significant responses. The response rate on day 7 was 86% (GM 58.10; 95% 
CI 50.04 to 67.45) and was highest when compared to the other time points. 
Responses started to wane by day 30 and decreased further on day 90 (GM 32.39; 
95% CI 28.32 to 38.30; P=0.5084) and day 180 (GM 23.69; 95% CI 20.99 to 26.74; 
P<0.0001) with a responder frequency of 72% and 42% respectively (Figure 3.9). 
 
 
 
 
 
Figure 3.9: Mean plasma Anti-CtxB specific IgG antibody response (with 
standard error). An asterisk indicates significant difference compared to baseline 
values (P<0.05). 
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3.5. OSP and LPS-specific IgA, IgG and IgM memory B cell 
response 
OSP and LPS specific IgA, IgG and IgM memory B cell using the ELISPOT 
technique was carried out assay at day 2, 30, 90 and 180 post onset of illness. After 
six day PBMC culture, only those that showed ≥3 fold increase in the number of total 
Immunoglobulin as compared to unstimulated cells were considered for analysis. 
Memory B-cells data were excluded from the analysis due to following reasons: 
4. The averaged total Ig samples for each patient-sample did not have appropriate 
stimulation. 
5. Patient samples had four or more antigen-specific ASC spots prior to 
stimulation.  
6. Patient samples had four or more ASC spots to the negative control antigen 
KLH. 
 
3.5.1. OSP and LPS- specific IgA memory B cell response 
It was observed that 58% patients responded with a significant OSP specific IgA 
memory B cell on day 30 when compared to baseline responses. Statistically 
significant response was also seen at day 180 (50%, P=0.0203) and day 90 (22%, P= 
0.0332) (Figure 3.10). 
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LPS specific IgA memory B cell response was significantly increased only at day 30 
(P= 0.0003) and respondent rate was about 97%. Response on day 90 (83%, P= 
0.0914) and 180 (87%, P= 0.1031) was higher comparing to day 2 responses (Figure 
3.11). But IgA memory B cells for LPS showed lowest respondent on day 2 (55%). 
          
 
 
 
Figure 3.10: Mean OSP-specific IgA memory B-cell response with (standard 
error). An asterisk indicates a statistically significant difference compared to 
baseline values (P<0.05). 
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3.5.2. OSP and LPS-specific IgG memory B cell response 
IgG memory B cells specific to OSP showed significant increase with gradually rising 
response. Although lower detectable response was seen day 2, an increased magnitude 
of response rose gradually on day 30 (53%, P=0.0079) and day 90 (46%, P=0.0054). 
Interestingly, the response remained significantly elevated up to day 180 (36%, 
P=0.0353) (Figure 3.12). 
On the other hand, LPS specific IgG memory B cell response were statistically 
significantly increased only on day 180 (P=0.0318) compared to the baseline 
response. Although detectable memory was 78% at day 2, it increased in the 
following day points on 30, 90 and 180 and it was 94%, 94% and 90% respectively 
(Figure 3.13). 
 
Figure 3.11: Mean LPS-specific IgA memory B-cell response (with standard 
error). An asterisk indicates a statistically significant difference compared to baseline 
values (P<0.05). 
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Figure 3.12: Mean OSP-specific IgG memory B-cell response (with standard 
error). An asterisk indicates a statistically significant difference compared to baseline 
values (P<0.05). 
Figure 3.13: Mean LPS-specific IgG memory B-cell response (with standard 
error). An asterisk indicates a statistically significant difference compared to baseline 
values (P<0.05). 
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3.5.3. OSP and LPS specific IgM memory B cell response 
The OSP specific memory B cell response was significantly increased at day 30 
(P=0.0186) and day 90 (P=0.0137) when compared to the day 2 responses; it 
decreased to the baseline level by day 180.  At day 2, detectable OSP specific IgM 
memory response was observed in 40% of patients and these rates increased on the 
following day points on 30, 90 and 180, it was seen in 72%, 94% and 53% of patients 
respectively (Figure 3.14).   
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Figure 3.14: Mean OSP-specific IgM memory B-cell response (with standard 
error). An asterisk indicates a statistically significant difference compared to baseline 
values (P<0.05). 
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The highest IgM memory B cell response for LPS was seen on day 90 (100%, 
P=0.0078). Response at day 180 was also significant (P=0.0391) with 74% 
respondent compared to day 2. High LPS specific IgM with 100% response observed 
at day 30 (P=0.0537) comparing to day 2, although was not statistically significant 
(Figure 3.15).   
Figure 3.15: Mean LPS specific IgM memory B-cell response (with standard 
error). An asterisk indicates a statistically significant difference compared to baseline 
values (P<0.05). 
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Studies in endemic areas of cholera have shown that the natural infection generates 
protective immunity to symptomatic disease on re-exposure for at least 3 years or 
perhaps as long as 10 years while available vaccine provides protection for 3-5 years 
in adults or shorter for younger children (6, 7). As the underlying mechanism of 
afforded longer protection by natural protection is not completely understood, an 
effective vaccine production is yet to be carried out. Although we know that LPS 
plays an important role in memory responses but available oral killed vaccines do not 
generate LPS targeted memory response (40, 81). 
Currently the most used marker for immunity to cholera is vibriocidal antibody titer 
which is yet to be defined (82), how this complement dependent antibody derived 
from plasma constituting mainly IgM antibody provides protection for the patients 
who have previously had cholera (33, 83). Although there is no such cut off 
vibriocidal titer at which complete protection against cholera is achieved (82), all the 
patients showed four fold increase in vibriocidal titer on all the study day points in 
this study, supporting previous findings (38,82, 83). Vibriocidal titer also correlates 
with LPS and OSP specific antibody responses where higher vibriocidal titer is 
associated with higher LPS and OSP specific antibody responses. This indicates that 
vibriocidal titer is a surrogate marker for antibody response (79). Cholera infection 
generates significant memory B cell responses to V. cholerae antigens LPS, CTB and 
TcpA (40). And in the majority of patients’ memory B cells remained detectable for at 
least 1 year with increased levels of IgA and IgG. Thus, antigen specific memory B 
cells may be useful markers for long term protection against cholera. Memory B cells 
are responsible for rapid immune response on re-exposure to the antigens. 
Furthermore, it is important to eliminate the antigens and pathogens that are not 
cleared by circulating antibodies even after the patient recovers from illness. Memory 
B cells may play an important role in replenishing the pool of  long lived plasma cells 
to maintain long term antibody level in circulation after removal of pathogens 
resulting in long lasting acquired immunity.  But it is not clear how long they are 
maintained in the absence of re-exposure to antigen. Measurement of antibody in 
memory B cells and availability of circulating plasma antibodies may be a better 
alternative than designing multiple antigen derived vaccine design. This study 
attempted to study memory response and circulating plasma antibody response to V. 
cholerae O1 and antigenic part of LPS (OSP) up to day 180. 
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However, LPS specific IgA antibody in duodenal biopsy may provide immunity to 
naturally infected cholera patient (83). Moreover, LPS can also develop memory B-
cell responses that may persist up to 180 days post infection, but wanes down by 1 
year (6). Kendall et al previously investigated LPS specific-IgM memory B cells 
response in memory B cell culture supernatants of cholera patients at day 2, day 30 
and 90 following onset of disease; and found that LPS specific antibody increased 
significantly at day 30 and 90 compared to the baseline. Furthermore, LPS specific 
IgA, IgG and IgM memory B cell responses were found up to day 180 in this current 
study. IgA memory B cell response was significantly elevated on day 30 among the 
study day points. Responses waned down in the following days but were higher 
compared to the baseline. In addition, LPS specific IgG memory B cell responses 
remained higher up to day 180 compared to the baseline. The presence of IgG specific 
memory B cell in the circulation was significantly higher on day 180. Anti-LPS IgM 
memory B cells were significantly detectable in circulation on days 90 and 180; 
responses were almost consistently high during the whole study period. LPS specific 
IgA, IgG and IgM plasma antibody response were also significantly detectable 
throughout the study point due to persistence of circulating memory B cells. 
LPS was also shown to generate immunity among household contacts of infected 
patients, and is thus an important candidate for vaccine design (72) or an antigenic 
component of it would be a more attractive one. Analysis for immune responses 
targeted to LPS was complicated because of its heterogeneous nature. O-specific 
polysaccharide (OSP) of V. cholerae defines serogroup specificity, most likely to 
contribute to the immune response to V. cholerae LPS.  It has already been shown that 
the OSP component of LPS was sufficient to detect immune responses comparable to 
those against LPS in patients infected with cholera (6) and was found to be associated 
with increased levels of vibriocidal antibody titer. The plasma antibody responses 
were also found correlated with vibriocidal antibody response in the same patients, 
indicating that responses against LPS, more specifically the antigenic O specific 
polysaccharide, OSP, mediate the observed vibriocidal antibody responses. In earlier 
studies, it was shown that there is a strong relationship between LPS and OSP 
response in the same patients (26). This indicates that the immune response to cholera 
infection specially targets the OSP component of V. cholerae LPS and also contribute 
to the vibriocidal antibody response.  
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As an antigenic part of LPS, the protective immunity generated by OSP was studied 
in this study. Interestingly OSP was found to generate memory B cells and was 
comparable to LPS generated memory B cell response. Unlike LPS, OSP specific IgA 
and IgG memory B cell generation was significant and responses remained elevated 
up to day 180 after onset of disease compared to baseline. Circulating plasma 
antibody levels for IgA and IgG were found to support findings for the circulating 
memory B cell responses. OSP specific IgM memory B cell response remained 
elevated up to day 90 and waned by day 180 but, was higher compared to the baseline 
response. Plasma IgA, IgG and IgM antibody response specific to OSP remained 
elevated and significant compared to the baseline response in all the study days after 
onset of cholera. 
Previous studies have shown that Anti-CTB (Cholera toxin B subunit) specific 
antibodies remain elevated in naturally cholera infected individuals and develop 
humoral immunity (85). There was no strong correlation between LPS and CTB 
specific plasma antibody elevation. But anti-LPS and CTB specific IgA antibodies 
may be associated with natural immunity against cholera infection (33). In earlier 
studies IgA, and IgG antibodies were found to be elevated up to day 30 while there 
was no significant increase in IgM levels (81) and suggested not to be associated with 
long term protection (40). This study revealed gradual decrease in plasma circulating 
IgA and IgG antibody after day 7 as was anticipated.  
In summary, currently available oral killed vaccines are not capable of providing long 
lasting immunity against cholera for subsequent re exposure over 5 years. A vaccine 
design capable of generating long lived memory B cells may be able to provide long 
lasting protective natural immunity in cholera endemic areas. As circulating OSP 
specific memory B cell response was found to be significantly persistent up to day 
180 and comparable to LPS specific memory B cell response when compared to all 
isotypes, a vaccine targeted to OSP would be an attractive option. Moreover, results 
were interesting enough to investigate OSP specific memory B cell persistence for 
long term protective immunity. Since OSP is the antigenic part of LPS and free of 
endotoxic portion the lipid A component, inclusion of OSP would be a safer and more 
reliable approach to design an effective vaccine capable of providing robust 
protection against cholera in the future. 
  
 
61 Discussion 
Limitations of present study: 
1. As enrolled patients for this study were V. cholerae O1 ogawa confirmed, 
response against Inaba is yet to study. 
2. Although 60 subjects were enough to study, study with greater subject numbers 
would produce result with more significance. 
 
Recommendation for future work 
1. Memory B cell responses against OSP can be demonstrated in vaccinees after 
vaccination with oral cholera vaccine. 
2. Determination of antibody avidity to OSP will be a worth target. 
3. Immune responses to OSP can be observed using biopsy specimen of cholera 
patients.    
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a. Used common laboratory apparatus 
Name Description Source 
ELISA plates 96-well Nunc™, Sweden 
EON Microplate Reader ELISA reader Bio-tek 
Eppendorf tubes 
sterilized by autoclaving at 
121°C for 20 minutes 
Eppendorf
®
 
Micropipette tips 
sterilized by autoclaving 
at121°C for 20 minutes 
Sigma 
Micropipettes  Thermo Lab systems 
Multi-channel Dispenser  Lab System, USA 
Petri dishes  Sterilin or Gibco 
Plastic tubes and 
pipettes 
 
Falcon
®
, Becton, 
Dickinson and Company 
Screw capped tubes 
and other glass wares 
 Pyrex
®
 Labware, USA 
Sorvall
®
 Legend™ XRT 
super speed centrifuge 
large-scale centrifugation Thermo Scientific 
Sorvall
®
 Pico microfuge Mini scale centrifugations Thermo Scientific 
Vacutainer tubes Heparin-coated, sterile 
Becton Dickinson, Ruther- 
ford, NJ 
 
b. Reagents Used 
1 
Acetic acid 
Sigma-758-12-3 
2 
BCIP (5-Bromo-4-Chloro-3-Indolyl Phosphate, Para Toludine Salt) 
Sigma, B8503 
3 
DMF (N, N-Dimethyl-Formamide) 
Sigma, D-8654 
4 
Ethydium Bromide 
Invitrogen, Scotland, UK 
5 FBS (Foetal Bovine Serum Albumin) 
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Gibco BRL- 16140-071 
6 
Ficoll 
Pharmacia LKB Biotechnology AB Uppsala, Sweden 
7 
Goat anti-human IgA-HRP 
Southern Biotechnology Associates, Inc. 2050-05 
8 
Goat anti-human IgG-AP 
Southern Biotechnology Associates, Inc. 2040-04 
9 
Goat anti-human IgM-HRP 
Hybridoma (Cat#HP6083) 
10 
H2O2 (Hydrogen Peroxide) 
Fisher Scientific, H-325 
11 
MgCl2 (Magnesium chloride 
Sigma-127-09-3 
12 
Na-acetate 
Sigma-127-09-3 
13 
NaCl (Sodiun Chloride) 
Fischer Scientific, Pittsburgh, PA, USA) 
14 
NaHCO3 (Sodium bi-carbonate) 
Fisher Scientific- S233-500 
15 
NBT (Nitro blue tetrazolium) 
BioRad, 170-6532 
16 
Rabbit anti-human IgA, anti-human IgG and anti-human IgM 
Jackson Immune Research Laboratories Inc. 
17 
Tween 20 (polyoxietylensorbitanmonolaurat) 
Sigma chemical Co., St. Louis, MO, USA 
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c. Buffer Solutions and Substrates 
Phosphate Buffer Saline (PBS) (10X) 
KCl (2.68 mM) 2.0 g 
Na2HPO4.12 H2O (7.7 mM) 27.5 g 
NaCl (0.136 M)                       80.0 g    
KH2PO4 (2 mM) 2.75 g 
pH 7.2 – 7.4 
For PBS- Tween 0.05% Tween 20 was added in 1X PBS 
 
1M Sodium Citrate (1000 mL) 
Trinatrium Citrate (Na3C6H5O4.2H2O)  29.4 g 
H2O (Deionized) 1000 mL 
pH 4.5 
 
Orthophenylene Diamine (OPD)-Hydrogen peroxide (Substrate) (10mL) 
OPD      10.0 mg 
0.1 M Sodium Cictrate                  10.0 mL 
30% H2O2                                      4.0 mL 
 
0.1% BSA PBS (500 ml) 
Phosphate Buffer Saline (PBS)   450 ml 
1% BSA in PBS 50 ml 
 
1% FBS PBS Tween (500 ml) 
Phosphate Buffer Saline (PBS) 450 ml 
1% BSA in PBS 50 ml 
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BCIP (4 ml) 
DMF 4ml 
BCIP 60 g 
 
NBT (4 ml) 
70% DMF 4 ml 
NBT 120 mg 
 
Carbonate buffer (1000 ml) 
0.1M NaHC03    8.4 g 
5mM MgCl2.6H20 1.0 g 
Deionized water 1000 ml 
 
ALP chromogen/substrate: BCIP/NBT (50 ml) 
BCIP (60 mg/4 ml 100% DMF) 0.5 ml 
NBT (120 mg/4 ml 70% DMF [2.8ml DMF+1.2ml dH2O]) 0.5 ml 
Carbonate Buffer 49 ml 
 
HRP chromogen /substrate: AEC/H2O2 (10 ml)             
AEC 10.0 mg 
DMF 1.0 ml 
The mixture is then dissolved in 30 mL of 0.1M sodium acetate buffer (16.4 g of 
0.2M Na-acetate dissolved in 1000 ml of distilled water, and then pH was adjusted 
to 5.0 with 0.2 M acetic acid). The AEC solution was filtered through 0.2µm 
Millipore filter and stored in a 50 ml plastic tube wrapped with aluminium foil. It 
remains stable at 4⁰C for a week. 
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Tryphan blue                                                                      
NaCl    0.81 g 
Tryphan blue 0.4 g 
KH2PO4      0.06 g 
Deionized water 100.0 ml 
 
d. Media Composition 
RPMI Complete (220 ml) 
RPMI 1640 (1X)  194 ml 
Fetal Bovine Serum (FBS- 10%)  20 ml 
Pcn/Strp (Penicillin-Streptomycin- 1%) 
Pen-10,000 IU/mL, Strep-10,000 ug/mL 
2 ml 
Na-Pyruvate 100 mM (1%) 2 ml 
L- Glutamine 200 mM (1%) 2 ml 
 
MBCS media (220 ml) 
RPMI 1640 (1X)  194 ml 
Fetal Bovine Serum (FBS- 10%)  20 ml 
Pcn/Strp (Penicillin-Streptomycin- 2%) 
Pen-10,000 IU/mL, Strep-10,000 ug/mL 
4ml 
L- Glutamine 200 mM (1%) 2 ml 
BME 22 µl 
 
TTGA Culture Media 
Trypticase (Casein) (BD) 10 g 
Nacl (BDH/MERCK) 10 g 
Sodium taurocholate (Sigma) 5 g 
Sodium carbonate (Sigma) 1.2-1.5 g 
Gelatin (BDH) 30 g 
Agar (BD) 16 g 
D/W 1 L 
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pH  8.5-9.0 
Boil, then sterilize at 15 Ibs pressure for 15-20 minutes. Before pouring the plates 
cool about 50⁰C, add potassium tellurite (K2TeO3)(5µg/ml). 
 
e. Software 
1. MS word 
2. Microsoft Excell 
3. Instat2 (Graph PAD Software 10855, USA)  
4. Endnote X7 
5. Ascent software 
 
 
 
